Page 171 - Personalised medicine of fluoropyrimidines using DPYD pharmacogenetics Carin Lunenburg

Supplementary Table 1. Demographic and clinical characteristics of DPYD variant allele carriers
0
1 (1%)
32 (38%) 24 (28%) 10 (12%) 6 (7%) 13 (15%)
14 (16%) 18 (21%) 31 (36%) 5 (6%)
1 (1%) 6 (7%) 5 (6%) 5 (6%)
1.9 [1.8─2.1] 39 (46%)
36 (42%) 4 (5%
6 (7%)
4 [1─8]
9 (56%)
3 (19%) 0 2 (13%) 0 1 (6%) 0 1 (6%) 0
2 (13%) 0 5 (31%) 0
26 (51%) 8 (47%) 18 (35%) 9 (53%) 3 (6%) 0
4 (8%) 0
4 [2─8] 3 [1─7]
4 (25%)
9 (56%) 0 1 (6%) 0 2 (13%) 0
3 [1─7] 3
(100%)
1 1 (6%) 0 1 (6%) 0 0 0 1 (6%) 0
(100%)
6 (38%)
0
0
2.0 2.1
Supplement
Characteristics
Sex
Male Female
Age
Median [IQR]
Ethnic origin
Caucasian African
Asian Othera
Tumor type
Non-metastatic CRC Metastatic CRC BC
GC Otherb
Type of treatment regimen
CAP mono CAP + RT CAPOX CAP other 5-FU mono 5-FU + RT FOLFOX 5-FU other
BSA
Median [IQR]
WHO performance status
0
1
2 NSc
Number of treatment cycles
Median [IQR]
DPYD variant allele carriers
N=85
48 (56%) 37 (44%)
c.1236G>A
N=51
26 (51%) 25 (49%)
0 0
15 (29%) 7 (40%) 17 (33%) 4 (24%) 5 (10%) 3 (18%) 4 (8%) 1 (6%) 10 (20%) 2 (12%)
8 (16%) 4 (24%) 8 (16%) 5 (29%) 19 (37%) 5 (29%) 3 (6%) 1 (6%) 0 0
6 (12%) 0
2 (4%) 2 (12%) 5 (10%) 0
1.9 2.0
[1.7─2.1] [1.7─2.1] [1.5─2.5]
c.2846A>T
N=17
11 (65%) 6 (35%)
0 0
DPYD*2A c.1679T>G
N=16 N=1
10 (63%)
6 (38%) 0
63 [54─71] 84 (99%)
62 [52─71] 51 (100%)
62 [53─72] 17 (100%)
1 (100%) 64 [58─70] 70
5
1 00000
(100%)
15 (94%)
0 0 1 (6%) 0
1 (100%)
1
a Other ethnic origins included Hispanic descent,
b Other tumor types included anal cancer, esophageal cancer, head and neck cancer, pancreas cancer, bladder cancer, unknown primary tumor, vulva carcinoma, and several rare tumor types;
c WHO performance status was not specified for these patients, but was either 0, 1, or 2, as this was required by the inclusion criteria of the study.
Abbreviations: 5-FU mono: 5-fluorouracil monotherapy; 5-FU other: 5-fluorouracil combined with
mixed-racial parentage and unknown ethnic origin;
169